Document is current
Any future updates will be listed below
-
Authors
Chan, Wei Yen
Lee, Jenny H.
Stewart, Ashleigh
Diefenbach, Russell J.
Gonzalez, Maria
Menzies, Alexander M.
Blank, Christian
Scolyer, Richard A.
Long, Georgina V.
Rizos, Helen http://orcid.org/0000-0002-2094-9198
-
Funding
Funding for this research was provided by:
National Health and Medical Research Council (National Health and Medical Research Council, National Health and Medical Research Council, National Health and Medical Research Council, National Health and Medical Research Council)
CLEARbridge Foundation (CLEARbridge Foundation)
Tour de Cure (Tour de Cure)
- License Information
-
More Information
Article History
Received: 27 May 2024
Accepted: 5 August 2024
First Online: 21 August 2024
Declarations
:
: Written consent was obtained from all patients and research complied with ethical regulation (Human Research ethics approval from Royal Prince Alfred Hospital Protocol No X15-0454 & 2019/ETH06874 and Protocol No X15-0311 & 2019/ETH06854). Plasma samples from consented healthy donors were acquired and analysed under Macquarie University Protocol No 2793.
: Not applicable.
: JL received honorarium from MSD, BMS, Sanofi, Roche, AstraZeneca, Novartis and sits of advisory boards for MSD, BMS and Sanofi. AMM has served on advisory boards for BMS, MSD, Novartis, Roche, Pierre-Fabre and QBiotics. RAS has received fees for professional services from SkylineDx BV, IO Biotech ApS, MetaOptima Technology Inc., F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, GlaxoSmithKline. GVL is consultant advisor for Agenus, Amgen, Array Biopharma, AstraZeneca, Bayer, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Evaxion, Hexal AG (Sandoz Company), Highlight Therapeutics S.L., IOBiotech, Immunocore, Innovent Biologics USA, Merck Sharpe & Dohme, Novartis, PHMR Ltd, Pierre Fabre, Regeneron, Scancell, SkylineDX B.V. All remaining authors have declared no conflicts of interest.
